Objective To evaluate the clinical value of serum superoxide dismutase (SOD) in anti-synthetase syndrome-related interstitial lung disease (ASyS-ILD). Methods We conducted a retrospective study of 153 patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD) at the Second Affiliated Hospital of Chongqing Medical University. Data collected included demographics, laboratory parameters [hemoglobin, absolute neutrophil count, absolute lymphocyte count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), creatine kinase (CK), lactate dehydrogenase (LDH), serum ferritin, serum superoxide dismutase (SOD), and myositis-specific antibodies], lung high-resolution computed tomography (HRCT) findings, treatment regimens, and recurrence. For comparison, serum SOD levels were also measured in 153 healthy individuals who served as the control group. Results Compared with the healthy control group, the serum SOD level in the ASyS-ILD group was significantly decreased (P < 0.001). The serum SOD level after treatment was higher than that before treatment (P < 0.001). In ASyS-ILD patients, the serum SOD level was significantly negatively correlated with ESR (r = − 0.281, P < 0.001); CRP (r = − 0.262, P < 0.001); CK (r = − 0.3678, P < 0.001); LDH (r = − 0.446, P < 0.001); and ferritin (r = − 0.508, P < 0.001). The serum SOD level in patients with anti-PL-7 antibodies was significantly lower than that in the anti-EJ group (P = 0.039). The serum SOD level in the ASyS-ILD recurrence group was significantly lower than that in the stable group (P = 0.001). The serum SOD level was an independent risk factor for disease recurrence in ASyS-ILD patients (P = 0.037). Conclusion In patients with ASyS-ILD, low serum SOD levels indicate the presence of oxidative stress. Serum SOD levels decrease in response to increasing inflammation in ASyS-ILD, suggesting that SOD can be used as a valid indicator of disease activity. The serum SOD levels in patients with ASyS-ILD are closely related to recurrence and deserve attention from rheumatologists.<Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry nameend="c2" namest="c1"> Key Points • Our study is the first to explore the relationship between SOD and ASyS-ILD. • This study demonstrates that SOD can serve as a simple and effective biomarker for evaluating the disease activity and recurrence of ASyS-ILD, which provides relevant information for clinical practice and a reliable basis for follow-up studies. </entry> </row> </tbody> </tgroup> </Table>

Evaluating the value of superoxide dismutase in anti-synthetase syndrome associated with interstitial lung disease

期刊论文
发表日期：

2026年4月9日

查看全文

Lei Luo,
Wenhan Huang,
Feifeng Ren,
Jun Zhou,
Zhihuan Zhang,
Hui Ke,
Lin Tang

摘要

Objective

To evaluate the clinical value of serum superoxide dismutase (SOD) in anti-synthetase syndrome-related interstitial lung disease (ASyS-ILD).

Methods

We conducted a retrospective study of 153 patients with anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD) at the Second Affiliated Hospital of Chongqing Medical University. Data collected included demographics, laboratory parameters [hemoglobin, absolute neutrophil count, absolute lymphocyte count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), creatine kinase (CK), lactate dehydrogenase (LDH), serum ferritin, serum superoxide dismutase (SOD), and myositis-specific antibodies], lung high-resolution computed tomography (HRCT) findings, treatment regimens, and recurrence. For comparison, serum SOD levels were also measured in 153 healthy individuals who served as the control group.

Results

Compared with the healthy control group, the serum SOD level in the ASyS-ILD group was significantly decreased (P < 0.001). The serum SOD level after treatment was higher than that before treatment (P < 0.001). In ASyS-ILD patients, the serum SOD level was significantly negatively correlated with ESR (r = − 0.281, P < 0.001); CRP (r = − 0.262, P < 0.001); CK (r = − 0.3678, P < 0.001); LDH (r = − 0.446, P < 0.001); and ferritin (r = − 0.508, P < 0.001). The serum SOD level in patients with anti-PL-7 antibodies was significantly lower than that in the anti-EJ group (P = 0.039). The serum SOD level in the ASyS-ILD recurrence group was significantly lower than that in the stable group (P = 0.001). The serum SOD level was an independent risk factor for disease recurrence in ASyS-ILD patients (P = 0.037).

Conclusion

In patients with ASyS-ILD, low serum SOD levels indicate the presence of oxidative stress. Serum SOD levels decrease in response to increasing inflammation in ASyS-ILD, suggesting that SOD can be used as a valid indicator of disease activity. The serum SOD levels in patients with ASyS-ILD are closely related to recurrence and deserve attention from rheumatologists.

Key Points

• Our study is the first to explore the relationship between SOD and ASyS-ILD.

• This study demonstrates that SOD can serve as a simple and effective biomarker for evaluating the disease activity and recurrence of ASyS-ILD, which provides relevant information for clinical practice and a reliable basis for follow-up studies.